Search for in this collection

Subscribe to this collection to receive daily e-mail notification of new additions

Preview	Issue Date	Title	Author(s)
	15-Apr-2026	AFM13 IN PATIENTS WITH R/R PERIPHERAL T CELL LYMPHOMA (PTCL): A POST-HOC SUBGROUP ANALYSIS FROM THE REDIRECT STUDY.	Kim W.-S.; Shortt J. ; Zinzani P.L.; Mikhaylova N.; Marin-Niebla A.; Radeski D.; Ribrag V.; Domenech E.D.; Sawas A.; Alexis K.; Emig M.; Garcia L.; Overesch A.; Pietzko K.; Horwitz S.
	15-Apr-2026	INTERVENTIONS AND THERAPY AT END OF LIFE IN HAEMATOLOGICAL MALIGNANCY: A RETROSPECTIVE COHORT STUDY ON HEALTHCARE UTILISATION.	Shaw B.; Parker C.; Shortt J. ; Opat S. ; Poon P.
	15-Apr-2026	PHASE 1B/2A STUDY OF AZD4573 (CDK9I) AND ACALABRUTINIB IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL).	Strati P.; Morschhauser F.; Danilov A.; Cheah C.; Shah H.; Jurczak W.; Olabode D.; Meyer S. ; Yoon J.L.; Arduini S.; Saeh J.; Olsson R.
	15-Apr-2026	UPDATED RESULTS FROM AN OPEN-LABEL PHASE 1/2 STUDY OF FAVEZELIMAB IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA AFTER ANTI-PD-1 TREATMENT.	Timmerman J.; Lavie D.; Johnson N.; Avigdor A.; Borchmann P.; Andreadis C.; Bazargan A.; Gregory G. ; Keane C.; Tzoran I.; Vucinic V.; Zinzani P.L.; West R.M.; Pillai P.; Marinello P.; Herrera A.F.
	16-Apr-2026	Implementing the ASCO PGA in a remote Australian setting.	Srivastava R.; Reardon L.; Pretorius T.; Fisher E.; Nelson J.; Hudson L.; McDonald J.; Huf J.; Iatropoulos G.; Pillai S.
	15-Apr-2026	POLATUZUMAB, BENDAMUSTINE & RITUXIMAB (POLA-BR) EFFICACY IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (RRDLBCL) TRIAL-INELIGIBLE PATIENTS: AN AUSTRALIAN LYMPHOMA REGISTRY (LARDR) STUDY.	Shaw B.; Chung E.; Wellard C.; Yoo E.; Bennett R.; Birks C.; Johnston A.; Cheah C.; Hamad N.; Simpson J.; Barraclough A.; Ku M.; Viiala N.; Ratnasingam S.; Armytage T.; Cochrane T. ; Chong G.; Lee D.; Manos K.; Keane C.; Wallwork S.; Opat S. ; Hawkes E.A.
	16-Apr-2026	One size doesn't FIT all: Early outcomes of implementing the ASCO PGA in an Australian public hospital.	Dumbrell J.; Moe T.; Nhung V.; McLeod V.; Rodrigues J.; Srivastava R.
	17-Mar-2026	The Role of Tumour Intrinsic Inflammasome Mutations in Lung Adenocarcinoma.	Gough D.
	17-Mar-2026	Treatment and Survival Outcomes for Indigenous Australians Within the Victorian Lung Cancer Registry.	Wright G.; Parakh S. ; Parente P. ; Stirling R.; Faisal W.; Gillies J.; Clark J.; Griffiths K.; Wood T.; Lesage J.; Briggs L.; Lloyd M.; Tissera S.; Zeng J.; Wong M.; Zalcberg J.; Harden S.; Atkin N.; Zeps N.; Conron M.; McQuilten Z. ; Moore M.; Adabi G.; Samuel E.; Lyne C.; Langton D.; See K.; Irving L.; Bartlett J.; John T.; Alexander M.; Richardson G.; Caldecott M.; Underhill C.; Blum R.; Torres J.
	17-Mar-2026	Real World Outcomes of First-Line Pembrolizumab With or Without Chemotherapy in Patients With NonSmall Cell Lung Cancer.	Alamgeer M. ; Briggs P. ; Sullivan I.; Laurence K.; Kwok A.; Paul E.; Pham R.; Arulananda S.
	17-Mar-2026	DYNAMALK: DYNAMic ct-DNA in ALK+ NSCLC Under the Australasian Thoracic Cancers Longitudinal Cohort Biobank Study (AURORA).	Rogers J.; Parakh S. ; Alexander M.; Solomon B.; Pavlakis N.; Hsing S.; Jain S.; Nagrial A.; Todd J.; Tazbirkova A.; Pokorny A.; Nahar K.; Clay T.; Golledge A.; Cannings J.; Ding P.; Abu Al-Hial F.; Roberts-Thomson R.; Takhar H.; Tay R.; Davis A. ; Arulananda S.; Atashrazm F.; Itchins M.; Bolton A.; McGrath A.; Briggs L.
	17-Mar-2026	Primary Endpoint Results from SHERLOCK: a Phase 2 trial of Sotorasib, Bevacizumab and Chemotherapy in Advanced KRAS G12C NSCLC.	Cummins M.M.; Lee C.K.; Arulananda S.; Zhou D.D.-X.; Brown C.S.B.; Bray V.; Ding P.; Itchins M.; Hughes B.G.M.; John T.; Pavlakis N.; Houghton B.; Chan B.; Black A.; Solomon B.J.; Roberts-Thomson R.; Mersiades A.J.; Bain N.; Yip S.; Barton K.; Parakh S. ; Stockler M.; Goodwin A.; Wall M.
	17-Mar-2026	Treatment Timeliness and Impact on Survival in Extensive Stage Small Cell Lung Cancer.	Alexander M.; Parente P. ; Stirling R.; Richardson G.; Hiong A.; Robinson J.; Paul E.; Zeng J.; Tissera S.; Zalcberg J.; Harden S.; Briggs L.; Lesage J.; Wood T.; Faisal W.; Torres J.; Underhill C.; Blum R.; Atkin N.; Caldecott M.; Parakh S. ; Irving L.; Lyne C.; Langton D.; See K.; Bartlett J.; John T.
	19-Mar-2026	The AUSSIE study: preliminary evaluation of Cxbladder Triage plus for urothelial carcinoma detection in patients with haematuria.	Vela I.; Ranasinghe W.; Hayne D.; Sethi K.; Buhariwalla V.
	19-Mar-2026	Morbidity and mortality outcomes associated with early anticoagulation recommencement following TURP.	Ramadas M.; Ranasinghe W.; Khanna Y.; Gordon E.
	19-Mar-2026	Prognostic significance of gleason grade at the surgical margin following radical prostatectomy.	Khanna Y.; Ranasinghe W.; Wei X.
	19-Mar-2026	Predictors of pathological upstaging from TURBT at radical cystectomy: a single-centre retrospective analysis.	Donnellan S. ; Wei X.; Khanna Y.; Huynh A.; Huang J.; Rajarubendra N.; Chu K.; Ranasingje W.
	19-Mar-2026	Grading the risk-comparing existing nomograms in predicting outcomes post radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC).	Ranasinghe W.; Khanna Y.; Huynh T.N.A.; Wei X.
	19-Mar-2026	Clinical characteristics and treatment outcomes in metastatic prostate cancer: a retrospective cohort analysis.	Ranasinghe W.; Ng K.W.
	18-Mar-2026	Impact of Timely Treatment Initiation on Outcomes in Non-Small Cell Lung Cancer. A Registry Based Observational Study.	See K.; Parakh S. ; Parente P. ; Irving L.; Robinson J.; Hiong A.; Zeng J.; Paul E.; Briggs L.; Wood T.; Stirling R.; Zalcberg J.; Lesage J.; Underhill C.; Faisal W.; Torres J.; Blum R.; Richardson G.; Caldecott M.; Olesen I.; Samuel E.; Lyne C.; McQuilten Z. ; Harden S.; Zeps N.; Atkin N.; Adabi G.; Conron M.; Moore M.; Wright G.; John T.; Langton D.; Bartlett J.